Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer

Peter R. Dottino, MD
Published: Monday, Sep 18, 2017



Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Researchers out of Mount Sinai out of their 10-year biobank to explore tumors to determine what the genetic make-up of the primary tumor, the recurrent tumor, and whether they can predict and find the same mutations in the primary tumor as in "second-look" washings, Dottino says. Using a 56-gene panel with next-generation sequencing, it was discovered that 5 patients had positive second-looks, with mutations in all washes. Three out of 5 patients who were classed as negative second-looks were later determined to still carry deleterious p53 mutations. These patients went on to have recurrent disease. 

This confirms that there is a heterogeneity to ovarian cancer, Dottino explains. 


Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Researchers out of Mount Sinai out of their 10-year biobank to explore tumors to determine what the genetic make-up of the primary tumor, the recurrent tumor, and whether they can predict and find the same mutations in the primary tumor as in "second-look" washings, Dottino says. Using a 56-gene panel with next-generation sequencing, it was discovered that 5 patients had positive second-looks, with mutations in all washes. Three out of 5 patients who were classed as negative second-looks were later determined to still carry deleterious p53 mutations. These patients went on to have recurrent disease. 

This confirms that there is a heterogeneity to ovarian cancer, Dottino explains. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x